Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review.
Brain chemical scans look interesting for autism but are still too shaky for daily use.
01Research in Context
What this study did
The authors read every proton MRS brain-imaging paper on autism up to 2013.
They looked for patterns in the chemicals that show up in brain scans.
No new data were collected; this is a story of what others have found.
What they found
Most studies saw lower levels of key brain chemicals in people with ASD.
The same chemical could be low in one study and normal in another.
The authors say the tool is promising but not ready for clinics.
How this fits with other research
İnci et al. (2021) used blood and urine tests, not brain scans, and still found rare metabolic errors in kids with ASD.
Their real-world screening adds a practical layer to the biochemical picture that Capio et al. (2013) only saw in scanners.
Naviaux (2026) later offered a theory that ties both sets of findings together: long-lasting cell danger response may drive both the scan changes and the metabolic errors.
Together, the three papers move from "we see odd chemicals" to "here is a possible reason why."
Why it matters
You cannot order a proton MRS scan today and get a clear yes-or-no about autism.
But you can watch for metabolic red flags—unusual labs, family history, or consanguinity—and refer for deeper screening when they appear.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add one metabolic screening question to your intake form: "Any rare metabolic disorders in the family?"
02At a glance
03Original abstract
Proton magnetic resonance spectroscopy ((1) H-MRS) is a safe, noninvasive way of quantifying in vivo biochemical and metabolite concentration levels in individuals with Autism Spectrum Disorders (ASD). Findings to date suggest ASD is associated with widespread reduction in N-acetylaspartate (NAA), creatine plus phosphocreatine (Cr), choline-containing compounds (Cho), myo-inositol (mI), and glutamate plus glutamine plus gamma-Aminobutyric Acid (Glx); however, variable findings, and even substantial increases, are not uncommon depending on the study and/or region-of-interest. Widespread reduction of NAA, Cr, Cho, mI, and Glx in ASD likely reflects impaired neuronal function and/or metabolism related to abnormal neurodevelopmental processes. Future studies should attempt to relate (1) H-MRS findings to histological findings and control for variability in subject age and functioning level; this would assist in evaluating the relationship between (1) H-MRS metabolic levels and neuronal and glial cell densities, as well as neurodevelopmental process associated with ASD. Furthermore, more longitudinal (1) H-MRS studies are needed in both control and ASD subjects to attempt to standardize metabolite levels across different developmental periods in well-defined endophenotypes. This will provide for a standard rubric for which metabolic aberrations (as well as treatment responses) can be measured. With higher magnetic field strengths and spectral-editing techniques capable of quantifying less-concentrated metabolites, (1) H-MRS will continue to be an important tool in ASD research.
Autism research : official journal of the International Society for Autism Research, 2013 · doi:10.1002/aur.1273